WeVote
Log In

Bill

Bill

RS 558

Para enmendar la Sección 3 de la Resolución del Senado 464, según aprobada el 11 de mayo de 2026, que le ordena a la Comisión de Salud del Senado de Puerto Rico realizar una exhaustiva investigación sobre el impacto que tiene en la salud de las personas la utilización de la sustancia Phenibut; y para otros fines relacionados.

2025-2028 Session

Sets a deadline for the Health Committee to deliver findings on Phenibut by the end of the Fourth Ordinary Session, replacing a 90-day window.

Texto de Aprobación Final en Senado
0
WeVote Research Nonpartisan
Bill Summary · RS 558

Overview

Bill RS 558 (Session 2025-2028, Puerto Rico) proposes an amendment to Section 3 of Senate Resolution 464, approved May 11, 2026. The underlying purpose of RS 464 is to require the Senate’s Health Committee to conduct a thorough investigation into the health impacts of using the substance Phenibut. RS 558 makes a targeted change to the deadline for delivering the final report.

Main purpose

  • To modify the reporting deadline in Section 3 of Senate Resolution 464.
  • The amendment affects when the Health Committee must present its findings, conclusions, and recommendations related to the health effects of Phenibut.

Key provisions

  • Section 1 (Amendment): Reads that Section 3 of Senate Resolution 464 shall be amended to require an expedited or clarified reporting timeline. Specifically, the clause changes the deadline language to state that the Senate will receive a detailed report “before the conclusion of the Fourth Ordinary Session” (as opposed to a prior phrasing that may have indicated a 90-day window after approval).
    • The text indicates removal of a prior 90-day requirement and replaces it with a deadline tied to the end of the Fourth Ordinary Session.
    • The report must include: findings, conclusions, and recommendations deemed necessary by the Committee.
  • Section 2 (Effective Date): The resolution takes effect immediately upon approval.

Who/what is affected

  • The Senate of Puerto Rico, specifically the Health Committee, and by extension any entity tasked with investigating Phenibut’s health impacts.
  • Stakeholders interested in the health implications of Phenibut, including public health officials, policymakers, researchers, and the general public seeking regulatory or health guidance.

Procedural/timeline aspects

  • The amendment aligns the reporting deadline with the end of the Fourth Ordinary Session, rather than a fixed 90-day period following approval.
  • The timing ensures the Health Committee completes the investigation within the current legislative session, potentially affecting the scope and sequencing of related hearings or data collection.
  • The measure is in the early stage: introduced June 29, 2026, and appears on first reading as of June 30, 2026.

Potential impact

  • Clarifies and potentially accelerates or finalizes the reporting schedule for the Phenibut health study.
  • Provides a concrete timeline for stakeholders awaiting Senate findings and recommendations regarding Phenibut.
  • Depending on the sufficiency of the Fourth Session’s duration, the deadline could influence the depth of analysis or require prioritization of the study within the committee’s workload.

Note: This summary focuses on the substantive changes introduced by RS 558 and its relation to RS 464. It does not include external factors or broader policy debates beyond the bill’s text and stated intent.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.